---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-122821"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2025-05-20T23:59:59+00:00"
generated_at: "2026-05-21T00:00:58.577122+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Viridian: 70% of veligrotug proptosis responders maintain response at week 52 in THRIVE trial

## Summary
- 70% of veligrotug proptosis responders (21/30) in THRIVE maintained response at week 52, defined as ≥2 mm reduction from baseline without fellow eye worsening.
- Safety profile unchanged in follow-up; majority of adverse events resolved by week 52.
- BLA submission for veligrotug in TED on track for H2 2025; company preparing for potential U.S. launch in 2026.
- Veligrotug received Breakthrough Therapy Designation, supporting Priority Review eligibility.

## SEC filing metadata
- accession: 0001193125-25-122821
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2025-05-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312525122821/0001193125-25-122821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312525122821/d938560d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-122821
- JSON: https://secwatch.observer/filing/0001193125-25-122821.json
- Plain text: https://secwatch.observer/filing/0001193125-25-122821.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.